日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

利拉夫替尼选择性抑制FGFR2的临床耐药机制。

Ellis H, Balasooriya E R, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent F W, Zhen Y, Silveira V S, Sellers W R, Corcoran R B, Juric D, Bardeesy N

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

获得的靶向改变导致对 p53-Y220C 激活剂的临床耐药性

Fece de la Cruz, Ferran; Varkaris, Andreas; Patel, Parasvi S; Kushner, Elijah W; Morales-Giron, Alvin A; Lee, Sangmi Sandra; Singh, Ankit; Kim, Clara T; Norden, Bryanna L; Ehnstrom, Sara; Riedl, Jakob M; Curtis, Jacquelyn M; Barnes, Haley; Kehlmann, Allison M; Chevalier, Nicholas J; Okuma, Hitomi S; Patel, Manisha; Wirth, Lori J; Connell, Brendan; Nugent, Francis; Pappas, Leontios; Lau, Kayao; Juric, Dejan; Hopkins, Jessica L; Guiley, Keelan Z; Shokat, Kevan M; Gulhan, Doga C; Parikh, Aparna R; Corcoran, Ryan B

FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.

FOXJ1 通过调节微管动力学介导紫杉烷类药物耐药性。

Xie Fang, Gjyrezi Ada, Fein Daniel, Labaf Maryam, Poluben Larysa, Ersoy-Fazlioglu Betul, Dennehy Christopher M, Voznesensky Olga, Gad Aniket, Corey Eva, Varkaris Andreas, Einstein David J, Bhatt Rupal S, Giannakakou Paraskevi, Balk Steven P

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

阐明针对致命性前列腺癌的 MCL1 分子分层单药和联合治疗策略。

Jiménez-Vacas Juan M, Westaby Daniel, Figueiredo Ines, De Haven Brandon Alexis, Padilha Ana, Yuan Wei, Seed George, Bogdan Denisa, Gurel Bora, Bertan Claudia, Miranda Susana, Lambros Maryou, Montero-Hidalgo Antonio J, Coleman Ilsa, Yu Ivan Pak Lok, Buroni Lorenzo, Zeng Wanting, Neeb Antje J, Welti Jon, Rekowski Jan, Paravati Roberta, Gabel Florian, Pandell Nicole, Ferreira Ana, Crespo Mateus, Riisnaes Ruth, Das Souvik, Taylor Joe, Waldron Nick, Hobern Emily, Valenti Melanie, Ning Jian, Bernett Ilona, Liodaki Kate, Persse Thomas, Galipeau Patricia, Wilkinson Scott, Trostel Shana Y, Karzai Fatima, Chau Cindy H, Beatson Erica L, Zhang Xiaohu, Klumpp-Thomas Carleen, Varkaris Andreas, Luque Raul M, Swain Amanda, Raynaud Florence, Lack Nathan A, Thomas Craig J, Ha Gavin, Figg William D, Bezzi Marco, Sowalsky Adam G, Nelson Peter S, Carreira Suzanne, Balk Steven P, de Bono Johann S, Sharp Adam

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.

靶向 BCL-XL 的 BH3 模拟物对 RB1 缺失和复制压力的实体瘤有效

Varkaris Andreas, Wang Keshan, Nouri Mannan, Kozlova Nina, Schmidt Daniel R, Stavridi Anastasia, Arai Seiji, Ambrosio Nicholas, Poluben Larysa, Jimenez-Vacas Juan M, Westaby Daniel, Carmichael Juliet, Xie Fang, Figueiredo Ines, Buroni Lorenzo, Neeb Antje, Gurel Bora, Chevalier Nicholas, Brown Lisha, Voznesensky Olga, Chen Shao-Yong, Russo Joshua W, Yuan Xin, Juric Dejan, Beltran Himisha, De Bono Johann S, Vander Heiden Matthew G, Einstein David J, Muranen Taru, Corey Eva, Sharp Adam, Balk Steven P

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

转移性乳腺癌患者中TOP1突变和抗体药物偶联物的交叉耐药性

Abelman Rachel O, Wu Bogang, Barnes Haley, Medford Arielle, Norden Bryanna, Putur Annika, Bitman Elena, Thant Win, Liu Ting, Weipert Caroline, Fell Geoffrey, Spring Laura M, Wander Seth A, Moy Beverly, Vidula Neelima, Isakoff Steven J, Varkaris Andreas, Juric Dejan, Corcoran Ryan B, Ellisen Leif W, Bardia Aditya

Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer

核因子 I 介导的染色质可及性增加驱动前列腺癌向雄激素受体剪接变体依赖性转变

Larysa Poluben ,Mannan Nouri ,Jiaqian Liang ,Shaoyong Chen ,Andreas Varkaris ,Betul Ersoy-Fazlioglu ,Olga Voznesensky ,Irene I Lee ,Xintao Qiu ,Laura Cato ,Ji-Heui Seo ,Matthew L Freedman ,Adam G Sowalsky ,Nathan A Lack ,Eva Corey ,Peter S Nelson ,Myles Brown ,Henry W Long ,Joshua W Russo ,Steven P Balk

Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

变构 PI3Kα 抑制剂可克服由继发性 PIK3CA 突变介导的对正构抑制剂的靶向耐药性

Andreas Varkaris #, Ferran Fece de la Cruz #, Elizabeth E Martin #, Bryanna L Norden, Nicholas Chevalier, Allison M Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi, Xin Yuan, Janice S Kim, Haley Ellis, Alkistis Papatheodoridi, Hakan Gunaydin, Brian P Danysh, Laxmi

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

RLY-2608 的发现和临床概念验证,这是一种一流的突变选择性变构 PI3Kα 抑制剂,可将抗肿瘤活性与高胰岛素血症分离开来

Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio #, Artemisa Bulku #, Lucian DiPietro, Cary Fridrich, Adam Frost, Fabrizio Giordanetto, Erika P Hamilton, Katherine Harris, Michael Holliday, Tamieka L Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jo

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity

BCL2表达在具有谱系可塑性特征的晚期前列腺癌中富集

Westaby, Daniel; Jiménez-Vacas, Juan M; Figueiredo, Ines; Rekowski, Jan; Pettinger, Claire; Gurel, Bora; Lundberg, Arian; Bogdan, Denisa; Buroni, Lorenzo; Neeb, Antje; Padilha, Ana; Taylor, Joe; Zeng, Wanting; Das, Souvik; Hobern, Emily; Riisnaes, Ruth; Crespo, Mateus; Miranda, Susana; Ferreira, Ana; Hanratty, Brian P; Nava Rodrigues, Daniel; Bertan, Claudia; Seed, George; Fenor de La Maza, Maria de Los Dolores; Guo, Christina; Carmichael, Juliet; Grochot, Rafael; Chandran, Khobe; Stavridi, Anastasia; Varkaris, Andreas; Stylianou, Nataly; Hollier, Brett G; Tunariu, Nina; Balk, Steven P; Carreira, Suzanne; Yuan, Wei; Nelson, Peter S; Corey, Eva; Haffner, Michael; de Bono, Johann; Sharp, Adam